Aberdeen Group plc Boosts Stock Position in LENZ Therapeutics, Inc. $LENZ

Aberdeen Group plc increased its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 76.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 130,726 shares of the company’s stock after acquiring an additional 56,440 shares during the quarter. Aberdeen Group plc owned approximately 0.46% of LENZ Therapeutics worth $6,089,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LENZ. Intech Investment Management LLC raised its position in shares of LENZ Therapeutics by 4.3% during the 2nd quarter. Intech Investment Management LLC now owns 9,251 shares of the company’s stock worth $271,000 after purchasing an additional 380 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in LENZ Therapeutics by 51.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after buying an additional 477 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of LENZ Therapeutics by 47.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company’s stock valued at $53,000 after acquiring an additional 586 shares during the last quarter. Bfsg LLC purchased a new position in shares of LENZ Therapeutics in the third quarter valued at approximately $30,000. Finally, Rhumbline Advisers lifted its position in shares of LENZ Therapeutics by 2.7% in the third quarter. Rhumbline Advisers now owns 25,019 shares of the company’s stock valued at $1,165,000 after acquiring an additional 656 shares in the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Down 3.8%

Shares of LENZ Therapeutics stock opened at $11.59 on Friday. The firm has a market cap of $362.65 million, a PE ratio of -5.49 and a beta of 0.50. LENZ Therapeutics, Inc. has a 52 week low of $11.50 and a 52 week high of $50.40. The business’s fifty day simple moving average is $16.26 and its 200-day simple moving average is $28.62.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Zacks Research lowered shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.